<abstract xmlns="http://www.w3.org/1999/xhtml">

<p>Neurological paraneoplastic syndromes (NPS) belong to a heterogeneous group of disorders affecting the nervous system. NPS occur as a result of immunological reaction to the tumor. As a result, the isolated syndrome is formed and manifests itself in many different ways, for example: limbic encephalitis, ataxia, dominant cerebellar degeneration, psychiatric disturbances, myasthenia gravis or diffuse encephalomyelitis. Detection of NPS is solely based on the presence of specific anti-neural antibodies. Although NPS had been previously considered unresponsive to therapy, some research has shown that there are effective therapies, including cancer- and immunotherapy targeted therapies.</p>
</abstract>

Neurological paraneoplastic syndromes (NPS) belong to a heterogeneous group of disorders affecting the nervous system. NPS occur as a result of immunological reaction to the tumor. As a result, the isolated syndrome is formed and manifests itself in many different ways, for example: limbic encephalitis, ataxia, dominant cerebellar degeneration, psychiatric disturbances, myasthenia gravis or diffuse encephalomyelitis. Detection of NPS is solely based on the presence of specific anti-neural antibodies. Although NPS had been previously considered unresponsive to therapy, some research has shown that there are effective therapies, including cancer- and immunotherapy targeted therapies.

Neurological manifestation of cancer – paraneoplastic syndromes

Department of Clinical Oncology and Chemotherapy

Current Issues in Pharmacy and Medical Sciences

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

{"article-title":"Neurological manifestation of cancer \u2013 paraneoplastic syndromes"}

Neurological paraneoplastic syndromes (NPS) belong to a heterogeneous group of disorders affecting the nervous system. NPS occur as a result of immunological...

Neurological manifestation of cancer – paraneoplastic syndromes

Publié en ligne: 15 juil. 2021

Pages: 74 - 76

Reçu: 01 févr. 2021

Accepté: 20 mai 2021

DOI: https://doi.org/10.2478/cipms-2021-0018

Mots clés
neurological paraneoplastic syndromes, cancer, antineural antibodies

© 2021 Katarzyna Szklener et al., published by Sciendo

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Neurological manifestation of cancer – paraneoplastic syndromes

Publié en ligne: 15 juil. 2021

Pages: 74 - 76

Reçu: 01 févr. 2021

Accepté: 20 mai 2021

DOI: https://doi.org/10.2478/cipms-2021-0018

Mots clésneurological paraneoplastic syndromes, cancer, antineural antibodies

© 2021 Katarzyna Szklener et al., published by Sciendo

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Mots clés
neurological paraneoplastic syndromes, cancer, antineural antibodies